Although continuous Imatinib therapy, especially in CML stage, leads to permanent responses, about 20 to 30 percent of CML patients show resistance to Imatinib therapy and only a few percent will improve and that is because of the secondary mutations in BCR-ABL1 and generating kinases. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.